Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Issued a Decision on the Regulation of Surgical Operations in Specialized Hospitals and Reminded Beauty Centers of the Legal Deadline Given until August to Settle their Situation

 
Deputy Prime Minister Health Minister Ghassan Hasbani held a press conference in his office at the Ministry of Public Health, Bir Hassan during which he tackled the organizational frames of beauty Centers and specialized hospitals.
He started by saying: “After the repetitive complaints received by the Ministry of Public Health on accidents and infringements occurring in the sector of Aesthetic Medicine, and as a result of what happened yesterday after the liposuction operation in a specialized hospital, we realized that it is our duty to inform you about the approach of the Ministry to the regulation of aesthetic sector and the actions taken and that being completed through regulatory actions."
 
Beauty Centers

He added: "The Ministry of Public Health followed up the work of the Parliamentary Health Commission for the regulation of Medical Beauty Centers licenses that resulted in the issuance of decision No. 30 of 10 February 2017, which was published in The Official gazette on February 16, 2017.  The Definition of Aesthetic Medicine, its centers and the medical work they are authorized to carry out are regulated by Law which has determined the medical specializations that have the right to hold a permission to practice the profession of Aesthetic medicine. According to the law, the existing Beauty Centers are given a 6 month period to regularize their legal situation as of the date of the publication of this law, i.e. 16 August 2017, under penalty of closing these centers by a decision of Health Minister.

Specialized Hospitals

Health Minister added that he has issued a regulatory decision for specialized hospitals related to the regulation of surgeries which stipulates the following:
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not be carried out in places other than specialized hospitals which include an intensive care division which holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent. 
Hasbani stressed that this decision will be immediately communicated to all concerned parties.

Death Case

Hasbani talked also about the recent tragic death of the woman who underwent a liposuction opertaion in a specialized hospital and said: “the Public Prosecution and the Syndicate of Physicians have launched investigations and the Ministry of Public Health has started to investigate and complete the files. The Committee of investigations will meet in the Ministry in order to consider the details of this case and provide consultancies to the Syndicate and Justice where needed.
    1
ATC Name B/G Ingredients Dosage Form ↑ Price
J01DD15 XEVANEER G Cefdinir - 300mg 300mg Capsule 1,350,562 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule L.L
A08AB01 XENICAL B Orlistat - 120mg 120mg Capsule 4,036,903 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
L02BB04 XTANDI B Enzalutamide - 40mg 40mg Capsule, soft 278,248,572 L.L
D07AC13 XEMADERM G Mometasone furoate - 0.1% 0.1% Cream 335,961 L.L
S01ED51 XOLAMOL G Timolol (maleate) - 5mg/ml, Dorzolamide HCl - 20mg/ml Drops solution 678,640 L.L
S01ED51 XALACOM B Timolol (maleate) - 6.8mg/ml, Latanoprost - 50?g/ml Drops solution 510,660 L.L
S01EE01 XALATAN B Latanoprost - 50mcg/ml 50mcg/ml Drops solution 704,173 L.L
S01EE01 XALAPROST G Latanoprost - 0.005% w/v 0.005% w/v Drops solution 421,967 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent 23,067,288 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 100 units LD50 100 units LD50 Injectable powder for solution 20,517,541 L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 50 units LD50 50 units LD50 Injectable powder for solution 11,920,109 L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable solution L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable solution 30,766,872 L.L
M05BX04 XGEVA BioTech Denosumab - 120mg 120mg Injectable solution 33,545,669 L.L
A10AE56 XULTOPHY BioTech Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml Injectable solution 13,503,847 L.L
A10AE56 XULTOPHY BioTech Insulin degludec - 100U/ml, Liraglutide - 3.6mg/ml Injectable solution 13,503,847 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 1,308,903 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 686,704 L.L
R01AA07 XYLO-COMOD G Xylometazoline HCl - 0.1% 0.1% Solution 498,566 L.L
H02AB06 XILONE FORTE G Prednisolone sodium phosphate - 15mg/5ml 15mg/5ml Solution 235,172 L.L
D04AB01 XYLOCAINE B Lidocaine - 10mg/spray dose 100mg/ml Spray 667,890 L.L
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet 3,006,579 L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet L.L
N05AX12 XALIPRO G Aripiprazole - 10mg 10mg Tablet 2,123,271 L.L
N05AX12 XALIPRO G Aripiprazole - 15mg 15mg Tablet 2,418,917 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026